OBJECTIVE: Chemotherapy is less often prescribed in older individuals due to concerns about post-treatment morbidity and quality of life. We evaluated the physical performance of breast cancer survivors treated with and without adjuvant chemotherapy. MATERIALS AND METHODS: We conducted a case-control study in 56 estrogen receptor positive breast cancer survivors (BCS) on adjuvant aromatase inhibitors 1-2years after definitive surgery. Cases had received adjuvant chemotherapy (n=27; age 70.5±3.6years) versus age-matched controls who had not (n=29; age 70.0±4.3years). Measures of grip strength, physical activity and performance, walking speed, fatigue, and self-reported physical function were collected. Biological correlates of inflammation, frailty and markers of DNA and RNA oxidation were compared. RESULTS: Grip strength (controls: 21±7.4 vs. CASES: 29.7±5.0kg, p=0.20), physical activity (5403±3204 vs. 6801±9320steps/day, p=0.45), physical performance (short physical performance battery score: 10.1±1.8 vs. 10.4±1.1, p=0.52) and long-distance walking speed (1.2±0.21 vs. 1.3±0.41m/s, p=0.17) were similar between the two groups. Self-reported physical function was marginally lower in cases than controls (controls: 72±24 vs. CASES: 57±34AU, p=0.07). Fatigue disruptiveness was not different between groups (controls: 11.1±13.0 vs. CASES: 15.7±16.2AU, p=0.24). Similarly, the inflammation, oxidation, and frailty markers did not present a significant difference between groups, except for vitamin D levels (p=0.04). CONCLUSION: Older women who received chemotherapy reported having slightly lower physical function, but a similar physical performance compared to women who did not. These data suggest that older BCS treated with chemotherapy recover to an extent similar to survivors who only received hormonal therapy.
OBJECTIVE: Chemotherapy is less often prescribed in older individuals due to concerns about post-treatment morbidity and quality of life. We evaluated the physical performance of breast cancer survivors treated with and without adjuvant chemotherapy. MATERIALS AND METHODS: We conducted a case-control study in 56 estrogen receptor positive breast cancer survivors (BCS) on adjuvant aromatase inhibitors 1-2years after definitive surgery. Cases had received adjuvant chemotherapy (n=27; age 70.5±3.6years) versus age-matched controls who had not (n=29; age 70.0±4.3years). Measures of grip strength, physical activity and performance, walking speed, fatigue, and self-reported physical function were collected. Biological correlates of inflammation, frailty and markers of DNA and RNA oxidation were compared. RESULTS: Grip strength (controls: 21±7.4 vs. CASES: 29.7±5.0kg, p=0.20), physical activity (5403±3204 vs. 6801±9320steps/day, p=0.45), physical performance (short physical performance battery score: 10.1±1.8 vs. 10.4±1.1, p=0.52) and long-distance walking speed (1.2±0.21 vs. 1.3±0.41m/s, p=0.17) were similar between the two groups. Self-reported physical function was marginally lower in cases than controls (controls: 72±24 vs. CASES: 57±34AU, p=0.07). Fatigue disruptiveness was not different between groups (controls: 11.1±13.0 vs. CASES: 15.7±16.2AU, p=0.24). Similarly, the inflammation, oxidation, and frailty markers did not present a significant difference between groups, except for vitamin D levels (p=0.04). CONCLUSION: Older women who received chemotherapy reported having slightly lower physical function, but a similar physical performance compared to women who did not. These data suggest that older BCS treated with chemotherapy recover to an extent similar to survivors who only received hormonal therapy.
Authors: Stephen M Haley; Alan M Jette; Wendy J Coster; Jill T Kooyoomjian; Suzette Levenson; Tim Heeren; Jacqueline Ashba Journal: J Gerontol A Biol Sci Med Sci Date: 2002-04 Impact factor: 6.053
Authors: Emanuele Marzetti; John M Lawler; Asimina Hiona; Todd Manini; Arnold Y Seo; Christiaan Leeuwenburgh Journal: Free Radic Biol Med Date: 2007-05-31 Impact factor: 7.376
Authors: Milan Chang; Jiska Cohen-Mansfield; Luigi Ferrucci; Suzanne Leveille; Stefano Volpato; Nathalie de Rekeneire; Jack M Guralnik Journal: J Am Geriatr Soc Date: 2004-12 Impact factor: 5.562
Authors: Brenda W J H Penninx; Stephen B Kritchevsky; Anne B Newman; Barbara J Nicklas; Eleanor M Simonsick; Susan Rubin; Michael Nevitt; Marjolein Visser; Tamara Harris; Marco Pahor Journal: J Am Geriatr Soc Date: 2004-07 Impact factor: 5.562
Authors: Richard P Troiano; David Berrigan; Kevin W Dodd; Louise C Mâsse; Timothy Tilert; Margaret McDowell Journal: Med Sci Sports Exerc Date: 2008-01 Impact factor: 5.411
Authors: Angela M Stover; Deborah K Mayer; Hyman Muss; Stephanie B Wheeler; Jessica C Lyons; Bryce B Reeve Journal: Cancer Date: 2014-03-19 Impact factor: 6.860
Authors: R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard Journal: Lancet Date: 2011-12-05 Impact factor: 79.321
Authors: Danielle B Tometich; Brent J Small; Judith E Carroll; Wanting Zhai; George Luta; Xingtao Zhou; Lindsay C Kobayashi; Tim Ahles; Andrew J Saykin; Jonathan D Clapp; Heather S L Jim; Paul B Jacobsen; Arti Hurria; Deena Graham; Brenna C McDonald; Neelima Denduluri; Martine Extermann; Claudine Isaacs; Asma Dilawari; James Root; Christine Rini; Jeanne S Mandelblatt Journal: J Pain Symptom Manage Date: 2018-11-23 Impact factor: 3.612
Authors: Yuan Yuan; Nilesh Vora; Can-Lan Sun; Daneng Li; Enrique Soto-Perez-de-Celis; Joanne Mortimer; The-Hang Luu; George Somlo; James Waisman; David Smith; Joseph Chao; Vani Katheria; Timothy Synold; Vivi Tran; Shu Mi; Abrahm Levi; Anait Arsenyan; Jennifer Choi; Laura Zavala; Susan Yost; Arti Hurria Journal: Breast Cancer Res Date: 2017-08-29 Impact factor: 6.466